Cellics Therapeutics

This cell membrane coating technology is a recent breakthrough in the field of nanomedicine. Our target is to treat all types of cancers with a single delivery platform. In animal studies, the delivery of mRNA and siRNA via CNP platform increases efficiency over 10 times and 7 times, respectively. Founded in 2016 in San Diego, CA, Cello has been committed to saving patients’ lives. Our objective is to accelerate the process of delivering novel and effective medical treatments to cancer patients’ hands. Cello is a biomedical company in San Diego, California, founded in 2016. Cello develops biomimetic cell membrane-coated nanoparticles for cancer drug delivery, including chemotherapy agents, immunotherapy agents, or mRNA.

Cellply is a deep tech company with the ambition to develop analytical tools enabling fast end effective development of life-saving cancer cell therapies. Our team features a unique combination of expertise in a diverse set of technology going from microfluidics to robotics, AI, biology and immunology. During Advanced Therapies Week 2024 in Miami we officially launched our flagship product, VivaCyte®.

Cell X is dedicated to advancing the promise of cellular therapies for innovators and patients alike. As Celligent operates, a wealth of invaluable data is gathered and stored in the CxKnowledge base. This comprehensive dataset is the bedrock for continuous advancements in Celligent's machine learning algorithm and is pivotal in establishing a program's proof of safety, efficacy, and reproducibility. With a passion for pushing the boundaries, our team has been purpose-built to foster an environment of innovation.

Our mission is to advance innovative solutions to unresolved chronic diseases and address the growing challenges of the biomedical industry through the promotion of translational research along with the development and commercialization of biotechnology platforms. We develop life-changing therapies and implants for unresolved chronic diseases and tackle the growing challenges of the biomedical industry through visionary life science tools. We aspire to become a world-renowned catalyst of regenerative medicine companies and products that contribute to enabling access to advanced medical treatments with high impact on patients’ health and well-being. Cells for Cells is strongly committed to time-sensitive and cost-efficient clinical and IP validation, a pledge that allowed us to achieve the first-ever clinical proof of principle of an exosome-produced therapy for joint disease. We aim to provide hope to patients in urgent need of satisfactory medical solutions by reducing cost and geographical barriers to accessing advanced therapeutic products. At Cells for Cells, we are devoted to quality. Since 2010, we have been Latin America’s leading company producing cell therapies and innovative tissue engineering solutions, each complying with national and international Good Manufacturing Practices (GMP) regulations related to quality and safety. We focus on continuous improvement thanks to our Quality Management System (QMS) based on ISO 9001:2015, our corporate values, and the experience and professionalism of our teams.

CELLnLIFE Inc. is a company that develops immune disease treatments using IntenCell®, an efficacy-enhancing stem cell. Based on the independently developed S-I-S culture platform technology, we are striving to overcome therapeutic efficiency limitations of stem cell therapy, thereby delivering healthy life and wellness to suffering patients with unmet medical needs. We are constantly challenging ourselves and do our best to grow into a company that can lead the global stem cell therapy market, while maintaining strong corporate ethics. 8th floor 50, Digital-ro 33-gil, Guro-gu, Seoul, Republic of Korea.

Celling Biosciences is a transformative leader innovating cellular therapy by integrating excellence in research, medical education, advocacy, and product development. Celling Biosciences is dedicated to the scientific understanding and therapeutic application of autologous cell therapy. Technologies developed by Celling Biosciences collect, process and deliver autologous cells to the patient at the point of care. The use of the patient’s own cells to promote healing provides a way of accelerating the body’s natural healing process. Celling Biosciences is a biotech company focused on the science, research and development of autologous cellular therapy. The ART PLUS Family of products is the only integrated ultra-filtration system on the market that allows for the processing of bone marrow, peripheral blood and growth factors at the point of care. The scientists and engineers behind Celling Biosciences have committed themselves to developing devices, techniques and clinical processes that optimize consistent, reliable, and reproducible cell therapy solutions. The product uses Celling Bioscience’s patented collection window and dial mechanism allowing precision control to achieve a high yield of platelets in a PRP volume that can be customized to the physician’s clinical requirements.